fidarestat has been researched along with neuropeptide y in 1 studies
| Studies (fidarestat) | Trials (fidarestat) | Recent Studies (post-2010) (fidarestat) | Studies (neuropeptide y) | Trials (neuropeptide y) | Recent Studies (post-2010) (neuropeptide y) |
|---|---|---|---|---|---|
| 97 | 3 | 33 | 10,663 | 152 | 2,269 |
| Protein | Taxonomy | fidarestat (IC50) | neuropeptide y (IC50) |
|---|---|---|---|
| Neuropeptide Y receptor type 1 | Homo sapiens (human) | 0.0014 | |
| Neuropeptide Y receptor type 2 | Homo sapiens (human) | 0.0003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dominguez, JM; Grant, MB; Yorek, MA | 1 |
1 other study(ies) available for fidarestat and neuropeptide y
| Article | Year |
|---|---|
Combination therapies prevent the neuropathic, proinflammatory characteristics of bone marrow in streptozotocin-induced diabetic rats.
Topics: Adipose Tissue; Animals; Bone Marrow; Cytokines; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Fish Oils; Gene Expression Regulation; Heterocyclic Compounds, 3-Ring; Hypoglycemic Agents; Imidazolidines; Inflammation; Insulin; Male; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidases; Neuropeptide Y; Nitric Oxide Synthase Type II; Pain Measurement; Rats; Rats, Sprague-Dawley; RNA, Messenger; Somatostatin; Stem Cells; Streptozocin; Thioctic Acid; Tyrosine 3-Monooxygenase | 2015 |